A detailed history of Gts Securities LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Gts Securities LLC holds 17,400 shares of ABCL stock, worth $46,806. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,400
Previous 14,000 24.29%
Holding current value
$46,806
Previous $41,000 9.76%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.39 - $3.49 $7,466 - $10,902
3,124 Added 17.02%
21,479 $55,000
Q2 2024

Aug 14, 2024

SELL
$2.73 - $4.73 $24,802 - $42,972
-9,085 Reduced 33.11%
18,355 $54,000
Q1 2024

May 15, 2024

SELL
$4.29 - $5.97 $18,481 - $25,718
-4,308 Reduced 13.57%
27,440 $124,000
Q4 2023

Feb 14, 2024

BUY
$3.91 - $5.93 $61,015 - $92,537
15,605 Added 96.67%
31,748 $181,000
Q3 2023

Nov 15, 2023

BUY
$4.6 - $7.95 $74,257 - $128,336
16,143 New
16,143 $74,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $767M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.